Erasca, Inc. (ERAS) vs Oruka Therapeutics, Inc. (ORKA)
A side-by-side comparison of Erasca, Inc. and Oruka Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ERAS
Erasca, Inc.
$14.27HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
ORKA
Oruka Therapeutics, Inc.
$79.42HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
Total return — ERAS vs ORKA
growth of $100 · dividends reinvested · last 5yERAS -15.5% (-3.3%/yr)ORKA +209.6% (+25.4%/yr)ORKA compounded faster over this window
ERAS ORKA
ERAS vs ORKA: by the numbers
- •ERAS is the larger company ($4.96B vs $4.79B market cap).
Metrics side by side
Valuation
| Metric | ERAS | ORKA |
|---|---|---|
| P/B ratio | 13.69 | 4.31 |
Profitability
| Metric | ERAS | ORKA |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -79.37% | -11.92% |
| ROIC | -38.03% | -13.88% |
Growth (annualized)
| Metric | ERAS | ORKA |
|---|---|---|
| Total return CAGR (5Y) | -8.34% | 32.76% |
Frequently asked
- How have ERAS and ORKA total returns compared?
- Over the past 5 years, ERAS delivered -8.34% and ORKA delivered 32.76% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.